Abstract
Allogeneic hematopoietic SCT (HSCT) for children with standard-risk AML in first CR (CR1) is controversial. We reviewed 32 consecutive children with standard-risk AML who received matched sibling donor HSCT in CR1 from 1995 to 2004. With a median follow-up of 76 months (range: 36–114), 3 year EFS was 0.74 (95% confidence interval (CI): 0.57–0.88) and the overall survival was 0.81 (95% CI: 0.66–0.93). Only one patient died as a result of TRM. Larger studies, such as the MRC-UK 10 and 12, reported 60–62% EFS. Outcome of children with standard-risk AML transplanted from a matched sibling donor in CR1 is very encouraging with minimal toxicity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Arceci RJ . Progress and controversies in the treatment of pediatric acute myelogenous leukemia. Curr Opin Hematol 2002; 9: 353–360.
Gibson BE, Wheatley K, Hann IM, Stevens RF, Webb D, Hills RK . Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005; 19: 2130–2138.
Frassoni F, Labopin M, Gluckman E, Prentice HG, Vernant JP, Zwaan F et al. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time—a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT). Bone Marrow Transplant 1996; 17: 13–18.
Michel G, Leverger G, Leblanc T, Nelken B, Baruchel A, Landman-Parker J et al. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Bone Marrow Transplant 1996; 17: 191–196.
Neudorf S, Sanders J, Kobrinsky N, Alonzo TA, Buxton AB, Gold S et al. Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood 2004; 103: 3655–3661.
Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE et al. Bone-marrow transplantation. N Engl J Med 1975; 292: 832–843, 895–902.
Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H et al. A controlled trial of fluconazole to prevent infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845–851.
Goodrich JM, Bowden RA, Fisher L, Keller C, Meyers JD . Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 18: 173–178.
Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA . Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized-blind study. Blood 1996; 88: 4063–4071.
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestation of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295–304.
Atkinson K, Horowitz MM, Gale RP, Lee MB, Rimm AA, Bortin MM . Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Bone Marrow Transplantation 1989; 4: 247–254.
Ringdén O, Labopin M, Tura S, Arcese W, Iriondo A, Zittoun R et al. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 1996; 93: 637–645.
Smith FO, Alonzo TA, Gerbing RB, Woods WG, Arceci RJ . Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia 2005; 19: 2054–2062.
Lange BJ, Smith FO, Feusner J, Barnard D, Dinndorf P, Feig S et al. Outcomes in CCG-2961, a Children's Oncology Group phase 3 trial for untreated pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood 2008; 111: 1044–1053.
Sung L, Lange BJ, Gerbing RB, Alonzo TA, Feusner J . Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood 2007; 110: 3532–3539.
Acknowledgements
The authors are indebted to the patients, patients' families, nursing and medical staff of the 8B unit and the oncology units at our partner centers for the provision of excellent patient care, which has been crucial for the achievement of the results reported here.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gassas, A., Afzal, S., Ishaqi, M. et al. Pediatric standard-risk AML with fully matched sibling donors: to transplant in first CR or not?. Bone Marrow Transplant 42, 393–396 (2008). https://doi.org/10.1038/bmt.2008.182
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2008.182